Product Description
Bosnalijek D.D is developing Metenkefalin as a treatment for Relapsing Remitting Multiple Sclerosis (RRMS). (Sourced from: https://clinicaltrials.gov/study/NCT03283397)
Mechanisms of Action: OPRD Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Bosnia
Approved Indications: None
Known Adverse Events: None
Company: Bosnalijek D.D
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Communicable Diseases|COVID-19|Multiple Sclerosis, Relapsing-Remitting
Phase 2: Pancreatic Cancer|Squamous Cell Carcinoma|Head and Neck Cancer
Phase 1: Hepatocellular Carcinoma|Liver Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00706576 |
NCT00706576 | P1 |
Completed |
Hepatocellular Carcinoma|Liver Cancer |
2013-07-01 |
2019-03-18 |
Treatments |
|
NCT00982696 |
PSU 23429 | P2 |
Terminated |
Squamous Cell Carcinoma|Head and Neck Cancer |
2011-11-01 |
2019-03-19 |
Treatments |
|
NCT00109941 |
OGF | P2 |
Completed |
Pancreatic Cancer |
2007-09-01 |
2019-03-22 |
Treatments |
|
NCT03283397 |
RAP-CS-01 | P3 |
Terminated |
Multiple Sclerosis, Relapsing-Remitting |
2023-07-01 |
17% |
2024-08-14 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT04374032 |
EN-COVCS-01 | P3 |
Completed |
Communicable Diseases|COVID-19 |
2020-10-07 |
16% |
2020-12-25 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |